In Brief: Xillix/Olympus
This article was originally published in The Gray Sheet
Xillix/Olympus: Sign letter of intent agreement under which Olympus would obtain worldwide distribution and marketing rights for Xillix' Life-Lung, Xillix says June 24. The deal expands an August 1994 agreement between the firms that appointed Olympus as distributor for the Life-Lung in Japan. FDA's Ear, Nose and Throat Panel recommended approval of the Life-Lung premarket approval application June 11 ("The Gray Sheet" June 17, p. 12). On June 27, Xillix announced receipt of regulatory approval to market the Life-Lung in France...
You may also be interested in...
Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.